Physician profile
Anthony Lee
NPI 1962639567
$555.34
in general payments reported to CMS, 2019-2025
11 companies · $97.74 in 2025
The $97.74 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $26.91 · 2022: $43.41 · 2023: $99.60 · 2024: $155 · 2025: $97.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $352.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $153.97 | 2023-2025 | Dysport |
| Abbvie INC. | $108.43 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $64.06 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $56.11 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $38.52 | 2025 | Xeomin |
| Ucb, INC. | $35.77 | 2019-2024 | Briviact |
| Otsuka America Pharmaceutical, INC. | $27.99 | 2023 | Nuedexta |
| Allergan, INC. | $24.59 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $17.13 | 2025 | |
| Sunovion Pharmaceuticals INC. | $14.58 | 2019 | |
| Pfizer INC. | $14.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.